Surgical treatment of primary cardiac tumors: 20-year single center experience

• Published in: Kardiochirurgia i torakochirurgia polska 2022-03, Vol.19 (1), p.36-40
• Main Authors: Děrgel, Martin, Gofus, Ján, Smolák, Petr, Stejskal, Václav, Hanke, Ivo, Matějka, Jan, Manďák, Jiří, Vojáček, Jan
• Format: Article
• Language: English
• Subjects: cardiac oncosurgery; Fibrillation; Heart; Heart surgery; Lipoma; long-term survival; Medical prognosis; Myxoma; Original Paper; Patients; primary cardiac tumor; Sarcoma; surgical resection; Survival; Tumors
• ISSN: 1731-5530; 1897-4252
• DOI: 10.5114/kitp.2022.114553

Primary cardiac tumors are a rare condition presenting with a variety of symptoms. The outcomes of their surgical treatment in the modern era from central Europe have not been recently reported. To evaluate the short- and long-term outcomes of the cardiac tumor operations at our department throughout the last 20 years. This was a retrospective analysis of all primary cardiac tumor operations performed at our institution between 2000 and 2020. Perioperative data were extracted from patient records. Long-term data were provided by the National Registry of Cardiac Surgery. Sixty procedures for primary cardiac tumor were performed throughout the study period. The most common type of tumor was myxoma (88%), followed by fibroelastoma (8%), lipoma (2%) and sarcoma (2%). There were 2 perioperative deaths (3%). The most common perioperative complication was atrial fibrillation (47%). One (2%) patient underwent reoperation 6 years later because of myxoma recurrence. We recorded 13 long-term deaths, but only 1 patient died as a consequence of cardiac tumor (sarcoma) 15 months after the surgery. Long-term survival of the cohort was comparable with the age- and sex-matched general population up to 15 years postoperatively (relative survival 0.91, CI 0.68-1.23). Rich histopathological illustrations are provided in the online supplementary material. Surgical resection is the standard treatment of primary cardiac tumors. The outcomes of benign tumors are excellent and the long-term postoperative survival is comparable with the general population. The prognosis of malignant tumors remains poor.